ERK/AKT Inactivation and Apoptosis Induction Associate With Quetiapine-inhibited Cell Survival and Invasion in Hepatocellular Carcinoma Cells

YEN-JU LEE1,2, JING-GUNG CHUNG3, ZHAO-LIN TAN2,3, FEI-TING HSU3, YU-CHANG LIU2,4,5* and SONG-SHEI LIN2*

1Department of Emergency Medicine, Zuoying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan, R.O.C.; 2Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.; 3Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.; 4Department of Radiation Oncology, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.; 5Department of Radiation Oncology, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.

Abstract. Background/Aim: Quetiapine, an atypical antipsychotic, has been encountered as a potential protective agent to suppress various types of tumor growth. However, the inhibitory mechanism of quetiapine in hepatocellular carcinoma (HCC) still remains unclear. The purpose of present study was to investigate the inhibitory mechanism of quetiapine on cell survival and invasion in HCC. Materials and Methods: Changes of apoptotic signaling, migration/invasion ability, and signaling transduction involved in cell survival and invasion were evaluated with flow cytometry, migration/invasion, and western blot assays. Results: Quetiapine inhibited cell proliferation and migration/invasion in SK-HeP1 and Hep3B cells. Quetiapine induced extrinsic and intrinsic apoptotic pathways. Activation of extracellular signal-regulated kinases (ERK), protein kinase B (AKT), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), expression of anti-apoptotic, and metastasis-associated proteins were decreased by quetiapine. Conclusion: The apoptosis induction, the decreased expression of ERK/AKT-mediated anti-apoptotic and the metastasis-associated proteins were associated with quetiapine-inhibited cell survival and invasion in HCC in vitro.

Antipsychotic medications are used for the treatment of patients with schizophrenia and other psychotic disorders (1). Recent epidemiological studies have focused on the relationship between cancer risk and the long-term use of antipsychotic drugs in patients with schizophrenia. Long-term antipsychotic treatment did not influence breast cancer risk, whereas risk of gastric or hepatocellular carcinoma (HCC) was reduced with antipsychotic use (2-4). Antipsychotic drugs have been shown to elicit anticancer response in various cancers. Sertindole, the second-generation antipsychotic drug, was presented to induce autophagy-associated apoptosis leading to tumor growth inhibition in breast cancer (5). Aripiprazole, the partial dopamine agonist used for treatment of schizophrenia, not only promoted cell growth inhibition but also increased sensitivity to chemotherapeutic agents in cancer stem cells (6). Quetiapine, the atypical antipsychotic, augments release of neurotransmitters leading to improvement of schizophrenia-negative symptoms (7). In addition to antipsychotic effect, quetiapine as the multifunctional agent has been demonstrated to modulate several biological properties such as anti-inflammation, neuroprotection, and anti-cancer effect (4, 8, 9). Quetiapine was presented to up-regulate differentiation of glioma stem cells and enhance anti-glioma efficacy of temozolomide (TMZ) (10). Quetiapine also attenuated breast cancer-induced osteolysis through blocking differentiation of osteoclasts (11). Chen 

This article is freely accessible online.

*These Authors contributed equally to this study.

Correspondence to: Song-Shei Lin, Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C. Tel: +886 4 22391647 ext. 7111, e-mail: sselin@ctust.edu.tw; Yu-Chang Liu, Department of Radiation Oncology, Show Chwan Memorial Hospital, Changhua 500, Taiwan, R.O.C. Tel: +886 422053366, ext. 2532, Fax: +886 422053366, e-mail: kevync.liu@gmail.com

Key Words: Quetiapine, hepatocellular carcinoma, ERK/AKT activation, apoptosis.
Figure 1. Continued
found quetiapine as the protective agent that reduced HCC risk in patients with schizophrenia. Furthermore, quetiapine also inhibited tumor cell growth and invasion ability in HCC in vitro (4). However, the anti-HCC mechanism of quetiapine has not been elucidated. Therefore, the major purpose of the present study was to verify the inhibitory mechanism of quetiapine on cell survival and invasion in HCC in vitro.

Materials and Methods

Chemicals and reagents. Quetiapine was purchased from Sigma-Aldrich (St. Louis, MO, USA). DMEM high glucose was purchased from Tseng Hsiang Life science LTD. Fetal bovine serum (FBS), L-glutamine, and penicillin streptomycin (PS) were purchased from Gibco/Life Technologies (Carlsbad, CA, USA). 3,3'-Dihexyloxacarbocyanine Iodide (DiOC<sub>6</sub>) was bought from Enzo Life Sciences (Farmingdale, NY, USA). RNase was bought from Fermentas (St. Leon-Rot, Baden-Wurttemberg, Germany). Propidium iodide (PI), CaspGLOW™ Fluorescein Active Caspase-3 Staining Kit, CaspGLOW™ Red Active Caspase-8 Staining Kit and Active Caspase-9 were all obtained from Biovision (Mountain View, CA, USA). MTT was purchased from Sigma-Aldrich. Matrigel and transwell (8-μm pore size) were purchased from Selleck Chemicals (Houston, TX, USA) and Corning Life Sciences (Tewksbury, MA, USA), respectively. MMP2 and MMP9 were bought from proteintech (Rosemont, IL, USA) and Millipore (Burlington, MA, USA), respectively. Further antibodies such as ERK (Thr202/Tyr204), ERK, AKT (Ser473), AKT, uPA, Survivin, MCL-1, VEGF, XIAP, β-actin were all bought from Elabscience (Houston, TX, USA).

Cell culture. Both SK-Hep1 and Hep3B human HCC cells used in this study were kindly provided from Professor Jing-Gung Chung’s lab, China Medical University, Taichung, Taiwan, ROC. Both SK-Hep1 and Hep3B cells were incubated in Dulbecco’s Modified Eagle Medium (DMEM) with high glucose, 10% FBS, 2mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin and maintained in 10 cm culture dish at 37°C with 5% carbon dioxide at a humidified incubator (12). Cell culture reagents and media were all purchased from Thermo Fisher Scientific (Fremont, CA, USA).

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. SK-Hep1 and Hep3B cells were seeded into 96-well plates each well with 5,000 cells/well and incubated overnight. Cells were treated with different concentration of quetiapine (0-320 μM) for 24 and 48 h. After treatment, medium was replaced by MTT solution (MTT 5 mg/ml in PBS: DMEM Medium, 1:9) for another 4 h incubation. Then, MTT solution was replaced by dimethyl sulfoxide (DMSO) to dissolve purple crystal. Finally, the viable

Figure 1. Induction of cytotoxicity and apoptosis by quetiapine in HCC. Cell viability of (A) SK-Hep1 and (B) Hep3B after quetiapine treatment are performed by MTT assay. (C) Annexin/PI staining pattern and (D) quantification data by flow cytometry after quetiapine treatment are displayed. After quetiapine treatment in HCC, (E) cell cycle analysis, (G) cleaved caspase-3 and (I) cleaved PARP-1 are also detected. Quantification results of (F) sub-G<sub>1</sub>, (H) cleaved caspase-3 and (J) cleaved PARP-1 are displayed. *p<0.05, **p<0.01 vs. 0 μM quetiapine.
cells signal was detected by ELISA reader (SpectraMax iD3) at 570 nm wavelength. The max dosage of quetiapine used in this study was followed by the inhibitory concentration 30 (IC₃₀) and the inhibitory concentration 50 (IC₅₀) on SK-Hep1 cells. This concentration (0, 108 and 216 μM) was used in consequent experiments on both SK-Hep1 and Hep3B cells treatment.

Annexin V/propidium iodide (PI) staining. Both SK-Hep1 and Hep3B cells were seeded into 6-well plates each well 5×10⁵ cells and incubated overnight. Cells were treated with 0, 108 and 216 μM quetiapine for 48 h. Cells were harvested by trypsin, stained with Annexin V/PI dye and incubated at 37˚C for 30 min. Cell population with Annexin V/PI-positive stain was detected and quantified by NovoCyte flow cytometry and NovoExpress® software (Agilent Technologies Inc., Santa Clara, CA, USA).

Cell cycle analysis. Both SK-Hep1 and Hep3B cells were seeded into 6-well plates each well 5×10⁵ cells and incubated overnight. Cells were treated with 0, 108 and 216 μM quetiapine for 48 h. Cells were harvested by trypsin, fixed with 75% ethanol by gently vortex and stored at –20˚C overnight. Cells were then washed with PBS and stained by PI/RNase at 37˚C for 30 min. Cell cycle was finally detected and quantified by NovoCyte flow cytometry and NovoExpress® software.

Figure 2. Activation of extrinsic apoptosis by quetiapine in HCC cells. (A) Fas activation pattern and (B) quantification bar chart are displayed after quetiapine treatment. (C) Fas-L activation pattern and (D) quantification bar chart are also shown. (E-F) The activation of cleaved caspase-8 and relative quantification results are both showed. *p<0.05, **p<0.01 vs. 0 μM quetiapine.
Cleaved Caspase-3, 8, 9, Fas, Fas-L, Ca$^{2+}$, loss of mitochondria membrane potential (DiOC$_6$) staining. Both SK-Hep1 and Hep3B cells were seeded into 6-well plates each well with 5×10$^5$ cells and incubated overnight. Cells were treated with 0, 108 and 216 μM quetiapine for 48 h. Cells were harvested by trypsin, stained with Cleaved Caspase-3 (FITC), -8 (PE), -9 (FITC), Fas (FITC), Fas-L, Ca$^{2+}$ (2.5 μg/ml Fluoro-3/AM, FITC), DiOC$_6$ (4 μM) dye, and followed by their own product protocols (13, 14).

Cleaved PARP-1 staining. Both SK-Hep1 and Hep3B cells were seeded into 6-well plates, each well with 5×10$^5$ cells and incubated overnight. Cells were treated with 0, 108 and 216 μM quetiapine for 48 h. Cells were harvested by trypsin, fixed with 4% formaldehyde for 15 min, permeabilized by ice-cold 100% methanol 30 min on ice, and freeze at -20°C in 90% methanol overnight. Cells were finally washed by PBS and stained by PARP1 staining dye (1% Bovine serum albumin and 0.3% Triton X in PBS with 1 μL PARP-1 dye) (15).

Transwell migration/invasion assay. Both SK-Hep1 and Hep3B cells were treated with different dose of quetiapine (0, 108 and 216 μM) for 48 h. After treatment, 3×10$^5$ cells were re-suspended in serum-free medium and placed in top well of transwell. Then, inserted the transwell into 24-well plate with 700 μl (w/well) high serum medium (300 μl FBS in 400 μl medium) for 24 h. Transwell membranes were then fixed with fixed buffer (acetid acid: methanol=1:3) for 15 min, washed with PBS, and stained with 0.3% crystal violet for 10 min. For invasion assay, 100 μl matrigel mixture (serum-free medium: matrigel=1:1) was added into transwell one day before cell inserted (16). Number of migration and invasion cells was quantified via ImageJ software version 1.50 (National Institutes of Health, Bethesda, MD, USA).

Western blotting. Both SK-Hep1 and Hep3B cells were seeded into 10 cm culture dish, incubated overnight, and treated with different doses of quetiapine (0, 108 and 216 μM) for 48 h. Cells were scraped in PBS, lysed by cell lysis buffer, followed with 10 mins’ sonication and centrifuged with 12000 rpm to extract total protein. Extracted proteins were quantified by BCA protein assay (Thermo Fisher Scientific). Proteins were mixed in 5x loading dye, separated by 8-12% SDS-PAGE and transferred to PVDF membranes. PVDF membranes were then added with primary antibodies overnight, and followed by 1 h secondary antibody incubation. The immunoreactivity bands were then visualized by Immobilon Western Chemiluminescent HRP Substrate kit (EMD Millipore) and detected by chemiluminescent image system (Xenogen, Alameda, CA, USA). Photon intensity emitted from cells was analyzed using living image ver.2.20.1 and normalized by cell viability (17).

Statistical analysis. Statistical analysis was performed by Microsoft excel one-way ANOVA and p-value <0.05 was defined as significant difference. Data are displayed as mean±standard deviation.

Results

Quetiapine induced cytotoxicity and apoptosis in HCC. To investigate the toxicity effect of quetiapine in HCC, we evaluated cell viability by the MTT assay. As shown in Figure 1A and B, the cytotoxicity effect of quetiapine was found in SK-Hep1 and Hep3B cells in a dose- and time-dependent manner. Then, we further investigated the apoptosis effect of quetiapine by Annexin/PI staining and cell-cycle assays. The percentages of early- and late-apoptosis populations were also found to be increased by quetiapine, as indicated in Figure 1C-D. As illustrated in Figure 1E-F, cells treated by quetiapine were markedly accumulated in the sub-G$_1$ phase in both SK-Hep1 and Hep3B cells. Additionally, the activation of cleaved caspase-3 after quetiapine treatment is displayed in Figure 1G-H. Figure 1I-J indicated that quetiapine may also induce the percentage of cleavage of PARP-1 which was also used as a marker of apoptosis effect. In sum, both toxicity and apoptosis effects were triggered by quetiapine on HCC.

Quetiapine activated extrinsic apoptotic pathway of hepatocellular carcinoma. To further evaluate the detailed mechanism of quetiapine on apoptosis signaling, we performed Fas, Fas-L and caspase-8 stain by cytometry. Fas activation was effectively increased by 48 h quetiapine treatment in SK-Hep1 and Hep3B cells (Figure 2A-B). The activation of Fas-L was also slightly increased by quetiapine, as shown in Figure 2C and D. Furthermore, caspase-8 was recognized as the downstream effector of death receptor-mediated apoptosis pathway. Thus, we also performed cleaved caspase-8 staining after 48 h quetiapine treatment on SK-Hep1 and Hep3B cells. In Figure 2E-F, the activation of cleaved caspase-8 was obviously induced by quetiapine as compared to non-treated control.

Quetiapine triggered intrinsic apoptotic pathway of HCC. After confirming the effect of quetiapine on extrinsic apoptosis mechanism, we further investigated whether intrinsic apoptosis may be also triggered by quetiapine. As illustrated in Figure 3A-B, the percentage of cellular calcium was markedly increased by quetiapine treatment on both SK-Hep1 and Hep3B cells. Moreover, the loss of mitochondria potential (Am) was also found in quetiapine treatment group (Figure 3C-D). Caspase-9, an important downstream effector of mitochondria-dependent apoptosis, was also validated.
after quetiapine treatment on HCC. In figure 3E and F, the activation pattern and quantification results both indicated the markedly induction of cleaved caspase-9 by quetiapine treatment. The intrinsic apoptosis mechanism was also induced by quetiapine on HCC cells.

Quetiapine diminished both migration and invasion ability of HCC cells. Other than apoptosis induction, we also investigated whether the migration and invasion effects of HCC may be suppressed by quetiapine. Here, we used with or without matigel transwell migration/invasion assay to identify the effects of quetiapine on HCC, respectively. Number of migration cells was effectively decreased by quetiapine treatment on both SK-Hep1 and Hep3B cells (Figure 4A-B). Furthermore, the invasion ability of HCC was also suppressed by quetiapine as indicated in figure 4C and
In conclusion, the migration and invasion capacity of HCC cells were both blocked by quetiapine. Quetiapine suppressed ERK, AKT, NF-κB activation, expression of anti-apoptotic, and metastasis-associated proteins in HCC cells. We explored the effect of quetiapine on activation of oncogenic kinases and transcription factor involved in regulation of cell survival and invasion in HCC cells. Effect of quetiapine on phosphorylation of ERK and AKT was evaluated with western blotting. As shown in Figure 5A, quetiapine reduced phosphorylation of ERK and AKT by 35-95% as compared to control group (0 μM quetiapine). Then, we further investigated the effect of quetiapine on NF-κB activation by NF-κB reporter gene assay. In Figure 5B-E presented quetiapine effectively decreased NF-κB activation by 30-75% as compared to control group in both SK-Hep1 and Hep3B cells. We further verified effect of quetiapine on anti-apoptotic and metastasis-associated proteins expression by Western blotting in both SK-Hep1 and Hep3B cells. As showed in 5F, Quetiapine diminished expression of anti-apoptotic proteins Survivin, XIAP, and MCL-
Figure 5. Inhibition of HCC progression-related proteins was associated with AKT/ERK/NF-κB inactivation by quetiapine. (A) The phosphorylation pattern of ERK and AKT are displayed. (B-C) NF-κB activation pattern and (D-E) quantification results after various doses of quetiapine treatment are shown. Both survival (F) and anti-apoptosis related and invasion/migration (G) and angiogenesis-related protein expression patterns after 0, 108, 216 μM quetiapine treatment on SK-Hep1 and Hep3B cells are displayed. *p<0.05, **p<0.01 vs. 0 μM quetiapine.
kinases, such as ERK and AKT participate in the κB activation (Figure 5B-E). The results also showed that quetiapine significantly reduced NF-κB-regulating expression of anti-apoptotic and metastasis-associated proteins leading to tumor progression (32, 33). In previous studies, suppression of NF-κB activation has been indicated to increase sensitivity to sorafenib (the anti-HCC drug) in HCC (24-26). Our results demonstrated quetiapine significantly induced apoptosis and promoted extrinsic/intrinsic apoptotic signaling transduction (Figures 2 and 3). Furthermore, as indicated by western blotting results, the expression of anti-apoptotic proteins (Figure 5F) were inhibited by quetiapine in HCC. We further indicated that quetiapine may suppress the phosphorylation of ERK and AKT in HCC cells. In conclusion, we provided information regarding the inhibitory mechanism of quetiapine on cell survival and invasion in HCC. We suggested that induction of apoptosis via extrinsic/intrinsic pathways, reduction of ERK/AKT-mediated anti-apoptotic pathways, and metastasis-associated proteins (MMP-9, MMP-2, uPA, and VEGF) expression are associated with quetiapine-inhibited cell survival and invasion in HCC in vitro.

In addition to NF-κB signaling, several oncogenic kinases, such as ERK and AKT participate in the promotion of cell survival and invasion through regulating expression of anti-apoptosis and metastasis-associated proteins in HCC. Suppression of both ERK and AKT activation reduce expression of anti-apoptotic and metastasis-associated proteins resulting in limitation of anti-apoptotic and invasion activity in HCC (13, 36-38). Furthermore, in previous studies investigating PD98059, the ERK inhibitor, attenuated NF-xB activation, but the AKT inhibitor did not, in HCC (35, 39). In our results, phosphorylation of ERK and AKT was alleviated with quetiapine treatment (Figure 5A).

Based on our results, we indicated that quetiapine may induce cytotoxicity and suppress tumor invasion/migration ability in HCC cells. We further indicated that quetiapine may trigger intrinsic and extrinsic apoptosis-related factors activation. Quetiapine may also suppress the phosphorylation of ERK and AKT in HCC cells. In conclusion, we provided information regarding the inhibitory mechanism of quetiapine on cell survival and invasion in HCC. We suggested that induction of apoptosis via extrinsic/intrinsic pathways, reduction of ERK/AKT-mediated anti-apoptotic (Survivin, XIAP, and MCL-1) and metastasis-associated proteins (MMP-9, MMP-2, uPA, and VEGF) expression are associated with quetiapine-inhibited cell survival and invasion in HCC in vitro.

Funding

This study was supported by a Grant from the Ministry of Science and Technology, Taipei, Taiwan (Grant number: MOST 108-2314-B-039-007-MY3), Zuoying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung (Grant number: ZBH 108-37) and Chang Bing Show Chwan Memorial Hospital, Changhua (Grant number: BRD-18010), respectively. This work was also financially supported by the “Drug Development Center, China Medical University” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.

Conflicts of Interest

The Authors declare that they have no conflicts of interest with the contents of this article.

Authors’ Contributions

Data curation: YJ Lee, ZL Tan, and FT Hsu. Funding acquisition: YJ Lee, FT Hsu and YC Liu. Writing, original draft: JG Chung, YJ Lee and FT Hsu; writing, review: JG Chung, YC Liu and SS Lin. All authors have read and agreed to the published version of the manuscript.

Acknowledgements

Experiments and data analysis were performed in part through the use of the Medical Research Core Facilities Center, Office of Research & Development at China Medical University, Taichung, Taiwan.
References

1. Lally J and MacCabe JH: Antipsychotic medication in schizophrenia: A review. Br Med Bull 114: 169-179, 2015. PMID: 25957394. DOI: 10.1093/bmbldv017

2. Pottegard A, Lash TL, Cronin-Fenton D, Ahern TP and Damkier P: Use of antipsychotics and risk of breast cancer: A Danish nationwide case-control study. Br J Clin Pharmacol 84: 2152-2161, 2018. PMID: 29858518. DOI: 10.1111/bcp.13661

3. Hsieh YH, Chan HL, Lin CF, Liang SH, Lu ML, McIntyre RS, Lee Y, Lin TC, Chiu WC and Chen VC: Antipsychotic use is inversely associated with gastric cancer risk: A nationwide population-based nested case-control study. Cancer Med 8: 4484-4496, 2019. PMID: 31183993. DOI: 10.1002/cam4.2329

4. Chen VC-H, Chan H-L, Hsu T-C, Lu M-L, Lee Y-C, Lee Y, Siow JY, McIntyre RS, Zhou AJ, Tzang B-S and Lee CT-C: New use for old drugs: The protective effect of atypical antipsychotics on hepatocellular carcinoma. Int J Cancer 144: 2428-2439, 2019. PMID: 30411796. DOI: 10.1002/ijc.31980

5. Zhang W, Zhang C, Liu F, Mao Y, Xu W, Fan T, Sun Q, He S, Chen Y, Guo W, Tan Y and Jiang Y: Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep 8: 15753-15753, 2018. PMID: 30361678. DOI: 10.1038/s41598-018-33740-0

6. Suzuki S, Okada M, Kuramoto K, Takeda H, Sakaki H, Watarai W, Zhang C, Liu F, Mao Y, Xu W, Fan T, Sun Q, He S, Chen Y, Guo W, Tan Y and Jiang Y: Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep 8: 15753-15753, 2018. PMID: 30361678. DOI: 10.1038/s41598-018-33740-0

7. Riedel M, Müller N, Strassnig M, Spellmann I, Severus E and Suzuki S, Okada M, Kuramoto K, Takeda H, Sakaki H, Watarai W, Zhang C, Liu F, Mao Y, Xu W, Fan T, Sun Q, He S, Chen Y, Guo W, Tan Y and Jiang Y: Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep 8: 15753-15753, 2018. PMID: 30361678. DOI: 10.1038/s41598-018-33740-0

8. Suzuki S, Okada M, Kuramoto K, Takeda H, Sakaki H, Watarai W, Zhang C, Liu F, Mao Y, Xu W, Fan T, Sun Q, He S, Chen Y, Guo W, Tan Y and Jiang Y: Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep 8: 15753-15753, 2018. PMID: 30361678. DOI: 10.1038/s41598-018-33740-0

9. Riedel M, Müller N, Strassnig M, Spellmann I, Severus E and Müller N, Strassnig M, Spellmann I, Severus E and Potter B, Lash TL, Cronin-Fenton D, Ahern TP and Damkier P: Use of antipsychotics and risk of breast cancer: A Danish nationwide case-control study. Br J Clin Pharmacol 84: 2152-2161, 2018. PMID: 29858518. DOI: 10.1111/bcp.13661

10. Hsieh YH, Chan HL, Lin CF, Liang SH, Lu ML, McIntyre RS, Lee Y, Lin TC, Chiu WC and Chen VC: Antipsychotic use is inversely associated with gastric cancer risk: A nationwide population-based nested case-control study. Cancer Med 8: 4484-4496, 2019. PMID: 31183993. DOI: 10.1002/cam4.2329

11. Chen VC-H, Chan H-L, Hsu T-C, Lu M-L, Lee Y-C, Lee Y, Siow JY, McIntyre RS, Zhou AJ, Tzang B-S and Lee CT-C: New use for old drugs: The protective effect of atypical antipsychotics on hepatocellular carcinoma. Int J Cancer 144: 2428-2439, 2019. PMID: 30411796. DOI: 10.1002/ijc.31980

12. Zhang W, Zhang C, Liu F, Mao Y, Xu W, Fan T, Sun Q, He S, Chen Y, Guo W, Tan Y and Jiang Y: Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep 8: 15753-15753, 2018. PMID: 30361678. DOI: 10.1038/s41598-018-33740-0

13. Zhang W, Zhang C, Liu F, Mao Y, Xu W, Fan T, Sun Q, He S, Chen Y, Guo W, Tan Y and Jiang Y: Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep 8: 15753-15753, 2018. PMID: 30361678. DOI: 10.1038/s41598-018-33740-0

14. Zhang W, Zhang C, Liu F, Mao Y, Xu W, Fan T, Sun Q, He S, Chen Y, Guo W, Tan Y and Jiang Y: Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep 8: 15753-15753, 2018. PMID: 30361678. DOI: 10.1038/s41598-018-33740-0

15. Zhang W, Zhang C, Liu F, Mao Y, Xu W, Fan T, Sun Q, He S, Chen Y, Guo W, Tan Y and Jiang Y: Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep 8: 15753-15753, 2018. PMID: 30361678. DOI: 10.1038/s41598-018-33740-0

16. Zhang W, Zhang C, Liu F, Mao Y, Xu W, Fan T, Sun Q, He S, Chen Y, Guo W, Tan Y and Jiang Y: Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep 8: 15753-15753, 2018. PMID: 30361678. DOI: 10.1038/s41598-018-33740-0

17. Zhang W, Zhang C, Liu F, Mao Y, Xu W, Fan T, Sun Q, He S, Chen Y, Guo W, Tan Y and Jiang Y: Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep 8: 15753-15753, 2018. PMID: 30361678. DOI: 10.1038/s41598-018-33740-0

18. Zhang W, Zhang C, Liu F, Mao Y, Xu W, Fan T, Sun Q, He S, Chen Y, Guo W, Tan Y and Jiang Y: Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep 8: 15753-15753, 2018. PMID: 30361678. DOI: 10.1038/s41598-018-33740-0

19. Zhang W, Zhang C, Liu F, Mao Y, Xu W, Fan T, Sun Q, He S, Chen Y, Guo W, Tan Y and Jiang Y: Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep 8: 15753-15753, 2018. PMID: 30361678. DOI: 10.1038/s41598-018-33740-0
growth by inducing intrinsic and extrinsic apoptotic pathways in hepatocellular carcinoma cells. Anticancer Res 37: 161-167, 2017. PMID: 28011486. DOI: 10.21873/anticanres.11301

25 Liu D, Fan Y, Li J, Cheng B, Lin W, Li X, Du J and Ling C: Inhibition of cflip overcomes acquired resistance to sorafenib via reducing er stressrelated autophagy in hepatocellular carcinoma. Oncol Rep 40: 2206-2214, 2018. PMID: 30066934. DOI: 10.3892/or.2018.6606

26 Hsu C, Lin LI, Cheng YC, Feng ZR, Shao YY, Cheng AL and Ou DL: Cyclin e1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through mcl-1 suppression. Clin Cancer Res 22: 2555-2564, 2016. PMID: 26603262. DOI: 10.1158/1078-0432.CCR-15-0499

27 Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY and Tang HB: Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 126: 641-646, 2000. PMID: 11079728. DOI: 10.1007/s0043200000146

28 Shim JH, Park JW, Kim JH, An M, Kong SY, Nam BH, Choi JI, Kim HB, Lee WJ and Kim CM: Association between increment of serum vegf level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 99: 2037-2044, 2008. PMID: 19016764. DOI: 10.1111/ j.1349-7006.2008.00909.x

29 Huang CF, Teng YH, Lu FJ, Hsu WH, Lin CL, Hung CC, Tung JN, Hsieh YH and Liu CJ: Beta-mangostin suppresses human hepatocellular carcinoma cell invasion through inhibition of mmp-2 and mmp-9 expression and activating the erk and jnk pathways. Environ Toxicol 32: 2360-2370, 2017. PMID: 28722351. DOI: 10.1002/tox.22449

30 Ghosh A, Dasgupta D, Ghosh A, Roychoudhury S, Kumar D, Gorain M, Butti R, Datta S, Agarwal S, Gupta S, Dhali G, Chowdhury A, Schmittgen T, Kundu G and Banerjee S: MiR199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting vegfa, vegfr1, vegfr2, hgf and mmp2. Cell Death & Disease 8: e2706, 2017. PMID: 28358369. DOI: 10.1038/cddis.2017.123

31 Wu MH, Chiu YF, Wu WJ, Wu PL, Lin CY, Lin CL, Hsieh YH and Liu CJ: Synergistic antimetastatic effect of cotreatment with licochalcone a and sorafenib on human hepatocellular carcinoma cells through the inactivation of mkk4/jnk and upa expression. Environ Toxicol 33: 1237-1244, 2018. PMID: 30187994. DOI: 10.1002/tox.22630

32 Xia Y, Shen S and Verma IM: Nf-kappab, an active player in human cancers. Cancer Immunol Res 2: 823-830, 2014. PMID: 25187272. DOI: 10.1158/2326-6066.CIR-14-0112

33 Huang SS, Deng JS, Lin JG, Lee CY and Huang GJ: Anti-inflammatory effects of trilinolein from panax notoginseng through the suppression of nf-kappab and mapk expression and proinflammatory cytokine expression. Am J Chin Med 42: 1485-1506, 2014. PMID: 25482678. DOI: 10.1142/S0192415X14500931

34 Liu YC, Wu RH and Wang WS: Regorafenib diminishes the expression and secretion of angiogenesis and metastasis associated proteins and inhibits cell invasion via nf-kappab inactivation in sk-hep1 cells. Oncol Lett 14: 461-467, 2017. PMID: 28693192. DOI: 10.3892/ol.2017.6142

35 Hsu FT, Liu YC, Chiang IT, Liu RS, Wang HE, Lin WJ and Hwang JJ: Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced erk/nf-kappab signaling. Int J Oncol 45: 177-188, 2014. PMID: 28693192. DOI: 10.3892/ol.2017.6142